
|Videos|October 5, 2016
The Significant Need for New Agents to Treat MDS
Author(s)Marco Davila, MD, PhD
Marco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the significant need for new agents to treat MDS.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















